Edition:
India

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,070JPY
18 Apr 2019
Change (% chg)

¥-149 (-3.53%)
Prev Close
¥4,219
Open
¥4,157
Day's High
¥4,157
Day's Low
¥4,061
Volume
8,450,300
Avg. Vol
10,514,574
52-wk High
¥5,127
52-wk Low
¥3,498

Latest Key Developments (Source: Significant Developments)

Lupus Therapeutics Partners With Takeda On Phase 1 Trial
Friday, 1 Mar 2019 

March 1 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::LUPUS THERAPEUTICS PARTNERS WITH TAKEDA ON PHASE 1 TRIAL.LUPUS THERAPEUTICS PARTNERS WITH TAKEDA ON PHASE 1 TRIAL.LUPUS RESEARCH ALLIANCE - CO, LUPUS THERAPEUTICS ANNOUNCED COLLABORATION WITH TAKEDA PHARMA TO EVALUATE INVESTIGATIONAL BIOLOGIC TAK-079.  Full Article

Takeda Pharmaceutical Co Ltd - Filed Shelf Registration For Issuance Of Up To 500 Billion Yen Aggregate Principal Amount Of Bonds
Friday, 15 Feb 2019 

Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA PHARMACEUTICAL CO LTD - FILED SHELF REGISTRATION FOR ISSUANCE OF UP TO 500 BILLION YEN AGGREGATE PRINCIPAL AMOUNT OF BONDS.TAKEDA PHARMACEUTICAL CO LTD - FILED AMENDED SHELF REGISTRATION FOR POTENTIAL PUBLIC OFFERING OF HYBRID BONDS.  Full Article

Takeda Says European Commission Approves Adcetris With Avd For Stage IV Hodgkin Lymphoma
Monday, 11 Feb 2019 

Feb 11 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA PHARMACEUTICAL- EUROPEAN COMMISSION APPROVES ADCETRIS WITH AVD FOR ADULTS WITH PREVIOUSLY UNTREATED CD30+ STAGE IV HODGKIN LYMPHOMA.  Full Article

Recursion and Takeda Extended Partnership; Financial Details Not Disclosed
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Recursion::RECURSION - TAKEDA, CO EXTENDED PARTNERSHIP TO ENABLE ADDITIONAL DISCOVERIES TO BE MADE & EVALUATED BY BOTH TEAMS; FINANCIAL DETAILS WERE NOT DISCLOSED.  Full Article

Takeda Pharmaceutical: Notice Regarding The Determination Of Subscription Requirements To Issue New Takeda Shares
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::NOTICE REGARDING THE DETERMINATION OF SUBSCRIPTION REQUIREMENTS TO ISSUE NEW TAKEDA SHARES.DETERMINED ON JAN 5 SUBSCRIPTION REQUIREMENTS TO ISSUE NEW TAKEDA SHARES AS A PART OF CONSIDERATION RELATING TO PROPOSED ACQUISITION OF SHIRE.  Full Article

Mersana Therapeutics Says XMT-1522 Development Discontinued Following Strategic Evaluation
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Mersana Therapeutics Inc ::MERSANA THERAPEUTICS ANNOUNCES STRATEGIC PRIORITIES AND GOALS FOR 2019 AND BEYOND.MERSANA THERAPEUTICS INC - XMT-1522 DEVELOPMENT DISCONTINUED FOLLOWING STRATEGIC EVALUATION.MERSANA THERAPEUTICS INC - DOSE SELECTION AND INITIATION OF XMT-1536 EXPANSION COHORTS ON TRACK FOR FIRST HALF 2019.MERSANA THERAPEUTICS - TO FOCUS RESOURCES ON ADVANCING XMT-1536, ITS FIRST-IN-CLASS ADC CANDIDATE TARGETING NAPI2B, SHOWING ENCOURAGING EARLY SIGNS OF EFFICACY.MERSANA THERAPEUTICS - FOR XMT-1536, EXPECTS TO SELECT DOSE FOR USE IN PHASE 1 EXPANSION STUDIES, INITIATE ENROLLMENT OF PATIENTS IN EXPANSION COHORTS IN H1 2019.MERSANA THERAPEUTICS INC - EXPECTS TO DISCLOSE ITS NEXT CLINICAL CANDIDATE IN SECOND HALF OF 2019.MERSANA THERAPEUTICS INC - MERSANA AND ITS PARTNER, TAKEDA, PLAN TO TERMINATE CO-DEVELOPMENT COLLABORATION FOR XMT-1522.MERSANA THERAPEUTICS INC - TARGETING FILING OF IND APPLICATION WITH FDA IN FIRST HALF OF 2020.MERSANA THERAPEUTICS INC - PROACTIVELY EVALUATING POTENTIAL FOR STRATEGIC COLLABORATIONS.  Full Article

Shire Says Jersey Court Sanctioned Scheme Of Arrangement For Takeda Deal
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Shire PLC ::REG-COURT SANCTION OF THE SCHEME.SHIRE PLC - ROYAL COURT OF JERSEY HAS TODAY SANCTIONED SCHEME OF ARRANGEMENT FOR TAKEDA DEAL.SHIRE - DE-LISTING OF SHIRE SHARES FROM LSE'S MAIN MARKET HAVE BEEN APPLIED FOR AND WILL TAKE EFFECT AT 8.00 A.M. (LONDON TIME) ON JANUARY 9, 2019.  Full Article

Takeda Pharmaceutical Cancels Bridge Credit Agreement
Friday, 21 Dec 2018 

Dec 21 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::STATEMENT REGARDING BRIDGE CANCELLATION.INTENDS TO FUND CASH CONSIDERATION DUE ON COMPLETION OF PROPOSED ACQUISITION OF SHIRE FROM ITS CASH RESOURCES AND OTHER FINANCING SOURCES.CANCELLED IN FULL REMAINING COMMITMENTS UNDER 364-DAY BRIDGE CREDIT AGREEMENT ENTERED INTO IN CONNECTION WITH THE ACQUISITION ON MAY 8.SOME TECHNICAL AMENDMENTS BEING MADE TO TERM LOAN CREDIT AGREEMENT DATED JUNE 8, SENIOR SHORT-TERM LOAN FACILITY AGREEMENT DATED OCT 26.  Full Article

Takeda Pharmaceutical to issue unsecured euro denominated senior notes worth 7.5 bln euros
Friday, 16 Nov 2018 

Nov 16(Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says it will issue unsecured euro denominated senior notes or an aggregate amount of 7.5 billion euros, with payment date on Nov. 21.The Notes will be issued in order to finance a portion of the funds necessary for the acquisition of Shire plc (the acquisition) and reduce commitments under the 364-Day Bridge Credit Agreement entered into in connection with the acquisition on May 8 (as amended on June 8 and Oct. 26) .  Full Article

Takeda Comments On Ongoing Review By European Commission Of Proposed Deal Of Shire PLC
Saturday, 27 Oct 2018 

Oct 26 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA COMMENTS ON ONGOING PHASE 1 REVIEW BY THE EUROPEAN COMMISSION OF THE PROPOSED ACQUISITION OF SHIRE PLC.TAKEDA - DOES NOT ANTICIPATE THAT DISCUSSIONS WITH EC WILL RESULT IN A DELAY TO ITS PREVIOUSLY ANNOUNCED TIMETABLE FOR COMPLETION OF TRANSACTION.TAKEDA -CONFIRMS IN DISCUSSIONS WITH EC IN RELATION TO FUTURE OVERLAP IN AREA OF INFLAMMATORY BOWEL DISEASE BETWEEN CO'S ENTYVIO & SHIRE'S SHP647.TAKEDA PHARMACEUTICAL CO LTD - CONFIRMS THERE ARE NO DISCUSSIONS WITH EC REGARDING ANY OTHER MARKETED PRODUCTS OR ASSETS IN PIPELINE.  Full Article

Photo

Japan's Takeda invites Brazilian pharmaceutical firms to bid for Latam business: sources

SAO PAULO/FRANKFURT Japan's Takeda Pharmaceutical Co Ltd has invited Brazilian pharmaceutical companies and financial investors to bid for its business in Latin America, three people with knowledge of the matter said.